Metastatic Colorectal Cancer
Oncology 3 original drugs 3
Novel Drugs
8
Reformulations
0
Active Trials
25
Drug Targets
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q2 2027
XLJDOD compound granule
Jiangsu Famous Medical Technology Co., Ltd.
Estimated · stale NCT05709249
Q3 2027
TQB2102 Injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Estimated · fresh NCT07483684
Q1 2028
Suvemcitug injection, trifluridine/tipiracil tablets
Jiangsu Simcere Pharmaceutical Co., Ltd.
Estimated · fresh NCT07361003
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 55 industry trials with a known mechanism of action.
Kinase Inhibitor
7 trials 3 active 5 sponsors
Programmed Death Receptor-1 Blocking Antibody
8 trials 1 active 4 sponsors
VEGFR-1/VEGFR-2/VEGFR-3
7 trials 1 active 3 sponsors
Vascular Endothelial Growth Factor Inhibitor
6 trials 1 active 3 sponsors
Nucleoside Metabolic Inhibitor
3 trials 1 active 3 sponsors
CTLA-4-directed Blocking Antibody
2 trials 1 active 1 sponsor
Programmed Death Ligand-1 Blocker
2 trials 1 active 2 sponsors
ALK/ROS1/NTRK1/TRKB/TRKC
1 trials 1 active 1 sponsor
AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3
1 trials 1 active 1 sponsor
Epidermal Growth Factor Receptor Antagonist
13 trials 6 sponsors
Vascular Endothelial Growth Factor Receptor 2 Antagonist
3 trials 1 sponsor
Poly(ADP-Ribose) Polymerase Inhibitor
2 trials 2 sponsors
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
791 industry-sponsored trials across 402 sponsors
Showing 7 of 7 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Takeda | Fruquintinib | VEGFR-1/VEGFR-2/VEGFR-3 | RECRUITING | 2027-10-04 | NCT06562543 |
| Bayer | Regorafenib (Stivarga, BAY73-4506) | — | COMPLETED | 2023-03-20 | NCT03564938 |
| Roche | 5-FU based doublet chemotherapy | — | COMPLETED | 2015-04-04 | NCT01695772 |
| Norgine | MOVIPREP | — | COMPLETED | 2013-01 | NCT01689792 |
| Roche | bevacizumab [Avastin] | — | COMPLETED | 2011-08 | NCT00577031 |
| Medtronic - MITG | — | — | TERMINATED | 2013-11 | NCT01706822 |
| Myriad Genetic Laboratories, Inc. | — | — | TERMINATED | 2012-08 | NCT01468623 |
Showing 86 of 86 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Shanghai Kechow Pharma, Inc. | Tunlametinib plus Vemurafenib | — | RECRUITING | 2026-12-24 | NCT06008119 |
| Jiangsu Famous Medical Technology Co., Ltd. | XLJDOD compound granule | — | RECRUITING | 2027-04-01 | NCT05709249 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | Suvemcitug injection, trifluridine/tipiracil tablets | — | RECRUITING | 2028-01 | NCT07361003 |
| Amgen | FOLFIRI Regimen | — | RECRUITING | 2028-01-31 | NCT06252649 |
| Summit Therapeutics | Drug: Ivonescimab Injection | — | RECRUITING | 2028-05-31 | NCT07228832 |
| Chipscreen Biosciences, Ltd. | Tucidinostat | — | RECRUITING | 2028-05-31 | NCT06497985 |
| AbbVie | Telisotuzumab Adizutecan | — | RECRUITING | 2028-10 | NCT06614192 |
| Incyte Corporation | INCA33890 | — | RECRUITING | 2028-12-29 | NCT07284849 |
| GE Healthcare | GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | — | RECRUITING | 2029-06 | NCT07219238 |
| EMD Serono Research & Development Institute, Inc. | Precemtabart tocentecan | — | RECRUITING | 2029-10-16 | NCT07549412 |
| Bristol-Myers Squibb | Pumitamig | — | RECRUITING | 2030-02-02 | NCT07221357 |
| Akeso | Cadonilimab (AK104) | — | RECRUITING | 2030-06-15 | NCT07412613 |
| Qilu Pharmaceutical Co., Ltd. | QL1706 | — | RECRUITING | 2030-12 | NCT06686576 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Adebrelimab in combination with SHR-8068 and chemotherapy | — | RECRUITING | 2032-11 | NCT07454720 |
| Shanghai Henlius Biotech | HLX10 | — | RECRUITING | 2025-09-24 | NCT04547166 |
| Shanghai Cingularbio Co. Ltd | — | — | RECRUITING | 2025-09-01 | NCT06968221 |
| Taizhou Hanzhong biomedical co. LTD | HX008(Pucotenlimab) | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT05652894 |
| Exelixis | XL092 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT05425940 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-A1811 | — | ACTIVE NOT RECRUITING | 2026-04 | NCT06199973 |
| Mirati Therapeutics Inc. | MRTX849 | — | ACTIVE NOT RECRUITING | 2026-01-16 | NCT04793958 |
| Jiangsu HengRui Medicine Co., Ltd. | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab | — | ACTIVE NOT RECRUITING | 2025-12-01 | NCT05945901 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anlotinib hydrochloride capsule | — | ACTIVE NOT RECRUITING | 2024-12-31 | NCT04854668 |
| Bristol-Myers Squibb | Ipilimumab | CTLA-4-directed Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2024-08-28 | NCT04008030 |
| Shanghai JMT-Bio Inc. | JMT101 | — | NOT YET RECRUITING | 2027-06-01 | NCT07134205 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQB2102 Injection | — | NOT YET RECRUITING | 2027-08 | NCT07483684 |
| Shanghai JMT-Bio Inc. | JSKN003 | — | NOT YET RECRUITING | 2027-11-30 | NCT07384377 |
| Qilu Pharmaceutical Co., Ltd. | QL1706 | — | NOT YET RECRUITING | 2028-07 | NCT07025239 |
| AbbVie | Telisotuzumab adizutecan | — | NOT YET RECRUITING | 2029-05 | NCT07525206 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | Enlituo® | — | NOT YET RECRUITING | 2029-10-01 | NCT07595276 |
| Vaccinogen Inc | OncoVAX and Surgery | — | NOT YET RECRUITING | 2031-08 | NCT02448173 |
| Immunophotonics, Inc. | 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water | — | NOT YET RECRUITING | 2033-12 | NCT07321847 |
| Amgen | Sotorasib | KRAS G12C | COMPLETED | 2025-07-16 | NCT05198934 |
| Merck | favezelimab/pembrolizumab | — | COMPLETED | 2024-08-15 | NCT05600309 |
| Merck | favezelimab/pembrolizumab | — | COMPLETED | 2024-08-15 | NCT05064059 |
| Merck | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | COMPLETED | 2023-03-27 | NCT04456699 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Double blind control period A140 | — | COMPLETED | 2023-03-22 | NCT04835142 |
| Isofol Medical AB | Arfolitixorin | — | COMPLETED | 2022-11-18 | NCT03750786 |
| Hutchison Medipharma Limited | Fruquintinib | VEGFR-1/VEGFR-2/VEGFR-3 | COMPLETED | 2022-07-29 | NCT04322539 |
| Taiho Oncology, Inc. | Trifluridine/Tipiracil | — | COMPLETED | 2022-07-19 | NCT04737187 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | CMAB009 | — | COMPLETED | 2022-05-06 | NCT03206151 |
| Takeda | oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | — | COMPLETED | 2022-01-14 | NCT02394795 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2021-02-01 | NCT03414983 |
| AB Science | Masitinib | — | COMPLETED | 2020-12 | NCT03556956 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Donafenib | — | COMPLETED | 2020-04-30 | NCT02870582 |
| Sumitomo Pharma America, Inc. | Napabucasin | — | COMPLETED | 2020-04-28 | NCT02753127 |
| Shanghai Henlius Biotech | HLX04 100 mg in 4 ml Injection | — | COMPLETED | 2020-04-15 | NCT03511963 |
| Pfizer | Encorafenib | — | COMPLETED | 2019-02-11 | NCT02928224 |
| Jiangsu HengRui Medicine Co., Ltd. | Famitinib | — | COMPLETED | 2019-02 | NCT02390947 |
| AryoGen Pharmed Co. | Bevacizumab + FOLFIRI-3 | — | COMPLETED | 2018-07-30 | NCT03288987 |
| Roche | Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody | — | COMPLETED | 2018-03-09 | NCT02788279 |
| Sanofi | AFLIBERCEPT AVE0005 | — | COMPLETED | 2017-01-31 | NCT01571284 |
| Hutchison Medipharma Limited | fruquintinib | VEGFR-1/VEGFR-2/VEGFR-3 | COMPLETED | 2017-01 | NCT02314819 |
| Sirtex Medical | FOLFOX6m | — | COMPLETED | 2016-12-23 | NCT01721954 |
| Cosmo Technologies Ltd | Methylene Blue MMX® | — | COMPLETED | 2016-10 | NCT01694966 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anlotinib | — | COMPLETED | 2016-08-18 | NCT02332499 |
| Taiho Pharmaceutical Co., Ltd. | TAS-102 | — | COMPLETED | 2016-02-16 | NCT01955837 |
| Merck KGaA, Darmstadt, Germany | Cetuximab | Epidermal Growth Factor Receptor Antagonist [EPC] | COMPLETED | 2016-01-25 | NCT01228734 |
| Johnson & Johnson | Xilonix | — | COMPLETED | 2015-11-30 | NCT02138422 |
| Norgine | NER1006, Day Before-Only Dosing | — | COMPLETED | 2015-08 | NCT02273141 |
| Norgine | NER1006, 2-Day Split-Dosing | — | COMPLETED | 2015-08 | NCT02273167 |
| Norgine | NER1006 | — | COMPLETED | 2015-06 | NCT02254486 |
| Sanofi | AFLIBERCEPT | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2015-06 | NCT01670721 |
| Sanofi | Aflibercept | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2014-10 | NCT01661270 |
| Eli Lilly | Ramucirumab | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | COMPLETED | 2014-07-17 | NCT01183780 |
| Amgen | Panitumumab | Epidermal Growth Factor Receptor Antagonist [EPC] | COMPLETED | 2014-06 | NCT01412957 |
| Taiho Oncology, Inc. | TAS-102 | — | COMPLETED | 2014-01-31 | NCT01607957 |
| Monsea Ltd. | — | — | COMPLETED | 2013-12 | NCT01410955 |
| Amgen | Cetuximab | Epidermal Growth Factor Receptor Antagonist [EPC] | COMPLETED | 2013-02-05 | NCT01001377 |
| Shanghai Zhangjiang Biotechnology Limited Company | CMAB009 plus Irinotecan | — | COMPLETED | 2012-12-23 | NCT01550055 |
| Amgen | Pegfilgrastim | Leukocyte Growth Factor [EPC] | COMPLETED | 2012-09-17 | NCT00911170 |
| Roche | Bevacizumab | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2012-05 | NCT00623805 |
| AEterna Zentaris | Capecitabine | Nucleoside Metabolic Inhibitor [EPC] | COMPLETED | 2012-04 | NCT01097018 |
| Bayer | Regorafenib (Stivarga, BAY73-4506) | — | COMPLETED | 2011-07 | NCT01103323 |
| Braintree Laboratories | BLI850 | — | COMPLETED | 2008-11 | NCT00756548 |
| Braintree Laboratories | BLI850 | — | COMPLETED | 2008-11 | NCT00756977 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-1701、 BP102 、XELOX | — | TERMINATED | 2024-04-17 | NCT04856787 |
| G1 Therapeutics, Inc. | Trilaciclib | — | TERMINATED | 2023-02-13 | NCT04607668 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | KL-140 | — | TERMINATED | 2021-11-27 | NCT03426371 |
| Egetis Therapeutics | Calmangafodipir (5 µmol/kg) | — | TERMINATED | 2020-08-31 | NCT04034355 |
| Egetis Therapeutics | Calmangafodipir (2 µmol/kg) | — | TERMINATED | 2020-08-31 | NCT03654729 |
| AB Science | Masitinib (AB1010) | — | TERMINATED | 2017-12 | NCT02605044 |
| Johnson & Johnson | Xilonix | — | TERMINATED | 2017-06-30 | NCT01767857 |
| HiberCell, Inc. | Imprime PGG + cetuximab | — | TERMINATED | 2017-02 | NCT01309126 |
| Symphogen A/S | Sym004 | — | WITHDRAWN | 2023-12 | NCT03717038 |
| Mirror Biologics, Inc. | AlloStim® | — | WITHDRAWN | 2019-12 | NCT01741038 |
| Roche | bevacizumab [Avastin] | — | WITHDRAWN | 2015-05 | NCT01338558 |
Showing 100 of 397 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Buzzard Pharmaceuticals | isunakinra | — | RECRUITING | 2026-06 | NCT06634875 |
| Bold Therapeutics, Inc. | BOLD-100 +/- FOLFOX Chemotherapy (Arm VII) | — | RECRUITING | 2026-06-01 | NCT04421820 |
| Portage Biotech | TT-10 | — | RECRUITING | 2026-06-01 | NCT04969315 |
| Medicenna Therapeutics, Inc. | MDNA11 | — | RECRUITING | 2026-06-30 | NCT05086692 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQB2922 injection ± TAS-102 tablets | — | RECRUITING | 2026-07 | NCT07044908 |
| PMV Pharmaceuticals, Inc | rezatapopt | — | RECRUITING | 2026-08-15 | NCT04585750 |
| MediLink Therapeutics (Suzhou) Co., Ltd. | YL202 | — | RECRUITING | 2026-08-31 | NCT07202364 |
| Kahr Bio Australia Pty Ltd | DSP107 + Atezolizumab | — | RECRUITING | 2026-09-30 | NCT07235293 |
| Suzhou Teligene Ltd. | TL938 Capsules | — | RECRUITING | 2026-10 | NCT06589830 |
| BeyondBio Inc. | BEY1107 | — | RECRUITING | 2026-11-30 | NCT05093907 |
| 858 Therapeutics, Inc. | ETX-19477 | — | RECRUITING | 2026-12 | NCT06395519 |
| Artios Pharma Ltd | ART0380 | — | RECRUITING | 2026-12 | NCT04657068 |
| Delcath Systems Inc. | Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab | — | RECRUITING | 2026-12 | NCT06607458 |
| One-carbon Therapeutics AB | TH9619 | — | RECRUITING | 2026-12 | NCT07151040 |
| Lumicell, Inc. | LUM015 | — | RECRUITING | 2026-12 | NCT02584244 |
| Sichuan Baili Pharmaceutical Co., Ltd. | SI-B003 | — | RECRUITING | 2026-12 | NCT06008054 |
| TiumBio Co., Ltd. | TU2218 + KEYTRUDA® (Pembrolizumab) | — | RECRUITING | 2026-12 | NCT05784688 |
| Shanghai Henlius Biotech | HLX43 Dose 1; | — | RECRUITING | 2026-12-30 | NCT07106892 |
| Jazz Pharmaceuticals | Zanidatamab | — | RECRUITING | 2026-12-31 | NCT06695845 |
| Shanghai Pharmaceuticals Holding Co., Ltd | SPH5030 | — | RECRUITING | 2026-12-31 | NCT06434597 |
| IDEAYA Biosciences | IDE196 | — | RECRUITING | 2027-01-29 | NCT03947385 |
| Neonc Technologies, Inc. | NEO212 Oral Capsule | — | RECRUITING | 2027-02-28 | NCT06047379 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC | — | RECRUITING | 2027-03-14 | NCT07589517 |
| NGM Biopharmaceuticals, Inc | NGM120 Q4W | — | RECRUITING | 2027-04 | NCT07033026 |
| Apollo Therapeutics Ltd | APL-5125 | — | RECRUITING | 2027-04 | NCT06399757 |
| Curacell Holding AB | CC-38 | — | RECRUITING | 2027-04 | NCT07255664 |
| Parabilis Medicines, Inc. | FOG-001 | — | RECRUITING | 2027-04-01 | NCT05919264 |
| Johnson & Johnson | Amivantamab IV | — | RECRUITING | 2027-04-27 | NCT05379595 |
| Revolution Medicines, Inc. | RMC-6236 | — | RECRUITING | 2027-05-15 | NCT06445062 |
| AstraZeneca | Volrustomig | — | RECRUITING | 2027-05-31 | NCT06792695 |
| Revolution Medicines, Inc. | RMC-6236 | — | RECRUITING | 2027-05-31 | NCT05379985 |
| ITM Oncologics GmbH | [68Ga]Ga-DPI-4452 | — | RECRUITING | 2027-06 | NCT05706129 |
| Crossignal Therapeutics, Inc. | CT3001 | — | RECRUITING | 2027-06-20 | NCT06598007 |
| Genfleet Therapeutics (Shanghai) Inc. | — | — | RECRUITING | 2027-07 | NCT07259590 |
| Oncolytics Biotech | Bevacizumab | Vascular Endothelial Growth Factor Inhibitor [EPC] | RECRUITING | 2027-08-30 | NCT07446322 |
| Stingray Therapeutics | SR-8541A | — | RECRUITING | 2027-09 | NCT06589440 |
| Frontier Medicines Corporation | FMC-376 | — | RECRUITING | 2027-10 | NCT06244771 |
| AstraZeneca | Datopotamab deruxtecan (Dato-DXd) | — | RECRUITING | 2027-10-01 | NCT05489211 |
| Radiopharm Theranostics, Ltd | 177Lu-BetaBart | — | RECRUITING | 2027-12 | NCT07189871 |
| Carina Biotech Limited | CNA3103: 5 x 10^7 cells | — | RECRUITING | 2027-12 | NCT05759728 |
| Riboscience, LLC. | RBS2418 | — | RECRUITING | 2027-12 | NCT06824064 |
| Neogap Therapeutics AB | pTTL | — | RECRUITING | 2027-12 | NCT05908643 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC (IV) | — | RECRUITING | 2027-12-21 | NCT07462650 |
| Shanghai EpimAb Biotherapeutics Co., Ltd. | EMB-01 1600 mg administered once weekly throughout the study | — | RECRUITING | 2027-12-30 | NCT07314294 |
| 7 Hills Pharma, LLC | Alintegimod | — | RECRUITING | 2027-12-31 | NCT06362369 |
| Criterium, Inc. | Fruquintinib+ Lonsurf (trifluridine and tipiracil) | — | RECRUITING | 2027-12-31 | NCT06992258 |
| Auricula Biosciences Inc. | WEF-001 | — | RECRUITING | 2028-01 | NCT07148128 |
| Perspective Therapeutics | [203Pb]Pb-PSV359 | — | RECRUITING | 2028-01-31 | NCT06710756 |
| Blue Earth Diagnostics | [18F]FPyQCP | — | RECRUITING | 2028-01-31 | NCT07432633 |
| Ono Pharmaceutical Co., Ltd. | ONO-4578 | — | RECRUITING | 2028-02-15 | NCT06948448 |
| AbbVie | Telisotuzumab Adizutecan | — | RECRUITING | 2028-03 | NCT06820463 |
| Isofol Medical AB | arfolitixorin (ARFOX + bevacizumab) | — | RECRUITING | 2028-03-31 | NCT06922383 |
| Anbogen Therapeutics, Inc. | ABT-301 | — | RECRUITING | 2028-04 | NCT07244705 |
| Betta Pharmaceuticals Co., Ltd. | MCLA-129 | — | RECRUITING | 2028-04-30 | NCT04930432 |
| A2 Biotherapeutics Inc. | A2B694 | — | RECRUITING | 2028-06 | NCT06051695 |
| Brenus Pharma | STC-1010 + IS regimen + SOC therapy | — | RECRUITING | 2028-06 | NCT06934538 |
| Bristol-Myers Squibb | BMS-986340 | — | RECRUITING | 2028-07-07 | NCT04895709 |
| ModeX Therapeutics, An OPKO Health Company | MDX2001 | — | RECRUITING | 2028-08 | NCT06239194 |
| Bristol-Myers Squibb | BMS-986523 | — | RECRUITING | 2028-10-13 | NCT07223047 |
| Revolution Medicines, Inc. | Elironrasib | — | RECRUITING | 2028-12 | NCT06128551 |
| Verastem, Inc. | VS-7375 | — | RECRUITING | 2028-12 | NCT07020221 |
| Tubulis GmbH | TUB-030 | — | RECRUITING | 2028-12 | NCT06657222 |
| Boehringer Ingelheim | Zongertinib | Kinase Inhibitor [EPC] | RECRUITING | 2029-01-08 | NCT06324357 |
| Eikon Therapeutics | EIK1005 | — | RECRUITING | 2029-03 | NCT07262619 |
| A2 Biotherapeutics Inc. | A2B395 | — | RECRUITING | 2029-03-31 | NCT06682793 |
| Alentis Therapeutics AG | ALE.P03 | — | RECRUITING | 2029-04-05 | NCT07169734 |
| Revolution Medicines, Inc. | Daraxonrasib | — | RECRUITING | 2029-05 | NCT07397338 |
| MBrace Therapeutics | ADC | — | RECRUITING | 2029-09-30 | NCT07145255 |
| Merck | Sacituzumab tirumotecan | — | RECRUITING | 2029-10-16 | NCT06428409 |
| AbbVie | Telisotuzumab Adizutecan | — | RECRUITING | 2029-11 | NCT07023289 |
| Hansoh BioMedical R&D Company | Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin | — | RECRUITING | 2029-12-31 | NCT07283367 |
| BioNTech SE | BNT314 | — | RECRUITING | 2030-12 | NCT07079631 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-8068 Injection | — | RECRUITING | 2031-10 | NCT07071714 |
| Chimeric Therapeutics | CHM-2101 CAR-T cells | — | RECRUITING | 2026-05 | NCT06055439 |
| NanoEcho AB | Iron oxide nanoparticles | — | RECRUITING | 2026-05 | NCT06693375 |
| Guangzhou JOYO Pharma Co., Ltd | JYP0015 | — | RECRUITING | 2026-03-30 | NCT06895031 |
| Apollomics Inc. | APL-101 Oral Capsules | — | RECRUITING | 2026-03-30 | NCT03175224 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI363 | — | RECRUITING | 2026-03-01 | NCT06281678 |
| Allist Pharmaceuticals, Inc. | JAB-21822 | — | RECRUITING | 2026-03 | NCT05288205 |
| Alethia Biotherapeutics | Sotevtamab | — | RECRUITING | 2026-03 | NCT06225843 |
| Chongqing Precision Biotech Co., Ltd | CEA-targeted CAR-T cells | — | RECRUITING | 2025-12-31 | NCT06006390 |
| Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | VB15010 | — | RECRUITING | 2025-12-30 | NCT06819215 |
| STCube, Inc. | Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab | — | RECRUITING | 2025-12 | NCT06873763 |
| GI Innovation, Inc. | GI-102 subcutaneous (SC) | — | RECRUITING | 2025-11-12 | NCT05824975 |
| Lantheus Medical Imaging | — | — | RECRUITING | 2025-11 | NCT06298916 |
| Merus B.V. | MCLA-158 | — | RECRUITING | 2025-11 | NCT03526835 |
| Evopoint Biosciences Inc. | XNW27011 | — | RECRUITING | 2025-06-30 | NCT06792435 |
| Vyriad, Inc. | VV1 | — | RECRUITING | 2025-06 | NCT04291105 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | SSGJ-707 | — | RECRUITING | 2025-06 | NCT06493760 |
| GeneMedicine Co., Ltd. | GM103 (Part A) | — | RECRUITING | 2025-05-30 | NCT06265025 |
| Jubaan Ltd. | — | — | RECRUITING | 2025-03-30 | NCT06612281 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-1701；Capecitabine；Oxaliplatin | — | RECRUITING | 2024-07-31 | NCT05300269 |
| Elpiscience (Suzhou) Biopharma, Ltd. | ES104 | — | ACTIVE NOT RECRUITING | 2026-05-31 | NCT05167448 |
| Pfizer | Encorafenib | — | ACTIVE NOT RECRUITING | 2026-06-01 | NCT05217446 |
| GSK | GSK4418959 | — | ACTIVE NOT RECRUITING | 2026-06-22 | NCT06710847 |
| OncoC4, Inc. | ONC-392 | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT04140526 |
| Novartis | JDQ443 | — | ACTIVE NOT RECRUITING | 2026-07-29 | NCT05358249 |
| BioNTech SE | RO7198457 intravenous (IV) | — | ACTIVE NOT RECRUITING | 2026-11 | NCT04486378 |
| Elicio Therapeutics | ELI-002 7P | — | ACTIVE NOT RECRUITING | 2026-11 | NCT05726864 |
| Cardiff Oncology | Onvansertib | — | ACTIVE NOT RECRUITING | 2026-11 | NCT06106308 |
Showing 100 of 301 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Sapience Therapeutics | ST316 | — | RECRUITING | 2026-05-31 | NCT05848739 |
| Qilu Pharmaceutical Co., Ltd. | QLC1101 | — | RECRUITING | 2026-05-31 | NCT06403735 |
| Sichuan Baili Pharmaceutical Co., Ltd. | BL-M17D1 | — | RECRUITING | 2026-08 | NCT06500052 |
| Angiex, Inc. | AGX101 | — | RECRUITING | 2026-09-06 | NCT06440005 |
| IDEAYA Biosciences | IDE-161 | — | RECRUITING | 2026-10 | NCT05787587 |
| EMD Serono Research & Development Institute, Inc. | M9140 | — | RECRUITING | 2026-10-23 | NCT05464030 |
| Hansoh BioMedical R&D Company | HS-20093 | — | RECRUITING | 2026-10-31 | NCT06825624 |
| Akamis Bio | NG-350A IV administration | — | RECRUITING | 2026-11-30 | NCT06459869 |
| Zumutor Biologics Inc. | ZM008 | — | RECRUITING | 2026-12 | NCT06451497 |
| BeiGene | BGB-53038 | — | RECRUITING | 2026-12 | NCT06585488 |
| Context Therapeutics Inc. | CT-95 | — | RECRUITING | 2026-12 | NCT06756035 |
| Monopar Therapeutics | MNPR-101-PCTA-177Lu | — | RECRUITING | 2026-12 | NCT06617169 |
| RasCal Therapeutics, Inc. | RSC-1255 Dose Escalation | — | RECRUITING | 2026-12-15 | NCT04678648 |
| Medigen Biotechnology Corporation | Magicell-NK contains NK cells suspended in 100 mL normal saline | — | RECRUITING | 2026-12-31 | NCT05394714 |
| Bicara Therapeutics | BCA101 | — | RECRUITING | 2026-12-31 | NCT04429542 |
| Chongqing Precision Biotech Co., Ltd | CEA-targeted CAR-T cells | — | RECRUITING | 2026-12-31 | NCT06043466 |
| Orano Med LLC | ²¹²Pb-DOTAM-GRPR1 | — | RECRUITING | 2027-01 | NCT05283330 |
| Kura Oncology, Inc. | Darlifarnib | — | RECRUITING | 2027-01 | NCT06026410 |
| ViroMissile, Inc. | IDOV-Immune (oncolytic vaccinia virus) | — | RECRUITING | 2027-01-31 | NCT06910657 |
| Mersana Therapeutics | XMT-2056 | — | RECRUITING | 2027-04 | NCT05514717 |
| Valo Therapeutics Oy | PeptiCRAd-1 | — | RECRUITING | 2027-04-30 | NCT05492682 |
| Sairopa B.V. | ADU-1805 | — | RECRUITING | 2027-05 | NCT05856981 |
| Vividion Therapeutics, Inc. | VVD-133214 | — | RECRUITING | 2027-05-31 | NCT06004245 |
| ALX Oncology Inc. | ALX2004 | — | RECRUITING | 2027-06 | NCT07085091 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Drug: IBI3028 | — | RECRUITING | 2027-06-30 | NCT07589205 |
| AbbVie | Azirkitug | — | RECRUITING | 2027-07 | NCT05005403 |
| IDEAYA Biosciences | IDE034 | — | RECRUITING | 2027-07-30 | NCT07503808 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-11818 | — | RECRUITING | 2027-08 | NCT06917079 |
| Pheon Therapeutics | PHN-012 | — | RECRUITING | 2027-09 | NCT07127874 |
| KaliVir Immunotherapeutics | VET3-TGI | — | RECRUITING | 2027-09-30 | NCT06444815 |
| MOMA Therapeutics | MOMA-341 | — | RECRUITING | 2027-11 | NCT06974110 |
| Iambic Therapeutics, Inc | IAM1363 | — | RECRUITING | 2027-12 | NCT06253871 |
| Sutro Biopharma, Inc. | STRO-004 | — | RECRUITING | 2027-12 | NCT07227168 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0610 for Injection | — | RECRUITING | 2027-12 | NCT07348211 |
| Fate Therapeutics | FT836 | — | RECRUITING | 2028-01 | NCT07216105 |
| Chongqing Precision Biotech Co., Ltd | CEA-targeted CAR-T cells | — | RECRUITING | 2028-03-31 | NCT07179692 |
| Revolution Medicines, Inc. | RMC-5127 | — | RECRUITING | 2028-04 | NCT07349537 |
| MacroGenics | MGC026 Dose Escalation | — | RECRUITING | 2028-05 | NCT06242470 |
| Lyell Immunopharma, Inc. | GCC19CART | — | RECRUITING | 2028-06 | NCT05319314 |
| ImmVirx Pty Ltd | IVX037 | — | RECRUITING | 2028-06-30 | NCT05427487 |
| Epkin | OKN4395 | — | RECRUITING | 2028-07 | NCT06789172 |
| Roche | Enzelkitug | — | RECRUITING | 2028-07-31 | NCT05581004 |
| PAQ Therapeutics, Inc. | PT0511 | — | RECRUITING | 2028-10-18 | NCT07300150 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-10203 | — | RECRUITING | 2028-11 | NCT06625775 |
| Astellas Pharma Inc | ASP5834 | — | RECRUITING | 2028-11-30 | NCT07094204 |
| Pfizer | PF-07799933 | — | RECRUITING | 2029-02-02 | NCT05355701 |
| Eli Lilly | LY3962673 | — | RECRUITING | 2029-03 | NCT06586515 |
| Cartography Biosciences | CBI-1214 | — | RECRUITING | 2029-04 | NCT07321106 |
| Pfizer | PF-08032562 | — | RECRUITING | 2029-04-14 | NCT07318805 |
| Alterome Therapeutics, Inc. | ALTA3263 | — | RECRUITING | 2029-05 | NCT06835569 |
| ArriVent BioPharma, Inc. | MRG007 | — | RECRUITING | 2029-05 | NCT07066657 |
| Novartis | 68Ga-NNS309 | — | RECRUITING | 2029-05-09 | NCT07261631 |
| Kumquat Biosciences Inc. | KQB365 | — | RECRUITING | 2029-06-30 | NCT06720987 |
| Exelixis | Zanzalintinib | — | RECRUITING | 2030-06-28 | NCT05176483 |
| Roche | Inavolisib | Kinase Inhibitor [EPC] | RECRUITING | 2030-08-31 | NCT04929223 |
| Novartis | [68Ga]Ga-NNS309 | — | RECRUITING | 2031-01-15 | NCT06562192 |
| Roche | SPLIT Abs | — | RECRUITING | 2034-02-12 | NCT07416552 |
| Dispatch Biotherapeutics | DISP-10 | — | RECRUITING | 2046-04 | NCT07544589 |
| R-Pharm | RPH-030 | — | RECRUITING | 2026-05-15 | NCT07543744 |
| Shanghai JMT-Bio Inc. | JMT203 Injection | — | RECRUITING | 2026-05-01 | NCT06868849 |
| JiaRay Group | JR8603 | — | RECRUITING | 2026-05 | NCT06783569 |
| Taiho Pharmaceutical Co., Ltd. | AB122 | — | RECRUITING | 2026-05 | NCT04999761 |
| Revolution Medicines, Inc. | RMC-9805 | — | RECRUITING | 2026-04-30 | NCT06040541 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10502 | — | RECRUITING | 2026-04-01 | NCT05740956 |
| Monopar Therapeutics | MNPR-101-DFO*-89Zr | — | RECRUITING | 2026-04 | NCT06337084 |
| Hansoh BioMedical R&D Company | HS-20117 combined HS-20093 | — | RECRUITING | 2026-03-30 | NCT06621563 |
| Chongqing Precision Biotech Co., Ltd | CEA-targeted CAR-T cells | — | RECRUITING | 2025-12-31 | NCT06126406 |
| Chongqing Precision Biotech Co., Ltd | CEA CAR-T cells | — | RECRUITING | 2025-12-31 | NCT06010862 |
| Rgenta Therapeutics Inc | RGT-61159 | — | RECRUITING | 2025-12 | NCT06462183 |
| Light Chain Bioscience - Novimmune SA | Biological NILK-2301 | — | RECRUITING | 2025-10 | NCT06663839 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | IM96 CAR-T Cells | — | RECRUITING | 2025-08-15 | NCT06718738 |
| BioEclipse Therapeutics | CRX100 suspension for infusion | — | RECRUITING | 2025-08 | NCT04282044 |
| Celyad Oncology SA | CYAD-101 | — | RECRUITING | 2023-08-21 | NCT04991948 |
| Celyad Oncology SA | CYAD-101 | — | RECRUITING | 2021-11-28 | NCT03692429 |
| Toray Industries, Inc | TRK-950 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT03872947 |
| TORL Biotherapeutics, LLC | TORL-3-600 | — | ACTIVE NOT RECRUITING | 2026-06-25 | NCT05948826 |
| OncoC4, Inc. | AI-061 | — | ACTIVE NOT RECRUITING | 2026-07-31 | NCT05858736 |
| Exelixis | XL092 | — | ACTIVE NOT RECRUITING | 2026-08-31 | NCT03845166 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | M9140 | — | ACTIVE NOT RECRUITING | 2026-09-30 | NCT06806046 |
| Novartis | DKY709 | — | ACTIVE NOT RECRUITING | 2026-10-30 | NCT03891953 |
| Pfizer | Tucatinib | Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05382364 |
| AgonOx, Inc. | DP CD8 TIL | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05902520 |
| HUYABIO International, LLC. | HBI-2438 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05485974 |
| HUYABIO International, LLC. | HBI-2376 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05163028 |
| Enliven Therapeutics | ELVN-002 | — | ACTIVE NOT RECRUITING | 2027-01 | NCT06328738 |
| NeoTX Therapeutics Ltd. | — | — | ACTIVE NOT RECRUITING | 2027-03-01 | NCT03983954 |
| Revolution Medicines, Inc. | RMC-6291 | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT05462717 |
| Novartis | HRO761 | — | ACTIVE NOT RECRUITING | 2027-08-31 | NCT05838768 |
| Ono Pharmaceutical Co., Ltd. | ONO-4578 | — | ACTIVE NOT RECRUITING | 2027-10-31 | NCT06547385 |
| AbbVie | ABBV-400 | — | ACTIVE NOT RECRUITING | 2027-11 | NCT05029882 |
| AbbVie | Telisotuzumab Adizutecan | — | ACTIVE NOT RECRUITING | 2027-12 | NCT06464692 |
| Roche | GDC-6036 | — | ACTIVE NOT RECRUITING | 2027-12-31 | NCT04449874 |
| Ono Pharmaceutical Co., Ltd. | ONO-7913 | — | ACTIVE NOT RECRUITING | 2027-12-31 | NCT06540261 |
| Eli Lilly | LY4066434. | — | ACTIVE NOT RECRUITING | 2030-01 | NCT06607185 |
| Poseida Therapeutics, Inc. | P-MUC1C-ALLO1 CAR-T cells | — | ACTIVE NOT RECRUITING | 2026-04 | NCT05239143 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | CEA protein antigen plus BCG Vaccine Mix for percutaneous use | — | ACTIVE NOT RECRUITING | 2026-02-28 | NCT02403505 |
| HiFiBiO Therapeutics | HFB200603 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05789069 |
| Harbour BioMed (Guangzhou) Co. Ltd. | HBM4003 | — | ACTIVE NOT RECRUITING | 2025-09-30 | NCT05167071 |
| Wugen, Inc. | WU-NK-101 - Dose Escalation | — | ACTIVE NOT RECRUITING | 2025-09-30 | NCT05674526 |
| DEKA Biosciences | DK210 (EGFR) | — | ACTIVE NOT RECRUITING | 2025-07 | NCT05704985 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Metastatic Colorectal Cancer
Novel Drugs by Company (New molecular entities)
Reformulations (8 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs